Business Wire

Arctic Blue Beverages to launch their first oat-based RTD

Share

Arctic Blue Beverages has launched Hang Oat Vanilla, their first oat-based ready-to-drink (RTD). The product is already on sale in Finland and will later this year be more widely available in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005604/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Arctic Blue Beverages has launched Hang Oat Vanilla, their first oat-based ready-to-drink (RTD). The product is already on sale in Finland and will later this year be more widely available in Europe. The novelty drink is based on the multi-award winning Arctic Blue Gin. “This new product expands our range of oat-based products. It is aimed especially at younger, conscious people, for whom sustainability is important, ”says Valtteri Eroma, CEO of Arctic Blue Beverages. (Photo: Business Wire)

The novelty drink is based on the multi-award winning Arctic Blue Gin. The oat-based drink combines the tastes of the wild northern nature and pure Finnish water. The drink is packed in Tetra Pak carton.

“This new product expands our range of oat-based products. It is aimed especially at younger, conscious people, for whom sustainability is important, ”says Valtteri Eroma, CEO of Arctic Blue Beverages.

Hang Oat Vanilla is Arctic Blue Beverages' first oat-based mild alcoholic beverage. In the future, the company intends to expand its RTD product range (ready-to-drink) by launching new flavors and packaging sizes both in Finland and abroad.

Eroma is pleased that Arctic Blue Beverages has the opportunity to respond to the rapidly growing trend of RTD beverages and the popularity of dairy-free oat products, and to develop new oat products.

“We have created an innovation platform that allows our product development to answer quickly to trends and market changes without taking months of development work, ”says Eroma.

According to Eroma, the market for RTD drinks has grown tremendously globally, and at the same time, oat-based options are taking up shelf space from traditional dairy products.

“Growth in both categories is immersive. With the new Hang Oat Vanilla just launched, we are among the first to take part in the growing segment, ”he says.

Arctic Blue Beverages Oy is a Finnish beverage company whose best-known products are the multi-award winning Arctic Blue Gin, Arctic Blue Gin Navy Strength and the world’s first dairy-free gin-based oat liqueur, Arctic Blue Oat. The company invests heavily in the export market and its products are sold in Japan, Australia and more than a dozen other countries globally.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Further information:
Valtteri Eroma
CEO & Head of Brand
+358 40 550 1343
valtteri.eroma@arcticbluebeverages.com

Anniina Nissinen
PR- & communications Agency Mellakka Helsinki
+358 400 380010
anniina.nissinen@mellakka.fi

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies20.11.2025 15:00:00 EET | Press release

Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies. Cassidy Bio’s AI-driven genomic foundation model combines proprietary wet-lab data, population-scale genomic insights, and advanced machine learning to predict the best pairings of guides, enzymes, and delivery modalities, matching them to optimal therapeutic contexts. This creates a scalable capability that supports an end-to-end workflow for genome editing at scale. By moving from siloed trial-and-error to a holistic, predictive approach, Cassidy aims to accelerate the discovery and development of safer, more reliable genetic medicines. “The promise of genome editing will

12 Major Verification Trends in 2026: Regula on the Birth of a New Digital Identity20.11.2025 15:00:00 EET | Press release

How we verify is changing — and so is who and what we verify. Are we dealing with real people, fraudsters, or machines acting on their behalf? A new Regula report on 12 identity verification trendsexamines how these shifts are forcing businesses to rebuild their verification processes to stay ahead of fraud, comply with regulations, and regain eroding customer confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120373343/en/ Identity is leaving the human domain: Regula’s forecast illustrates the emerging need to verify systems, autonomous agents, and machine customers. The new face of fraud The identity threat landscape has entered a new industrial phase, defined by three structural shifts: Machine identity. Identity verification (IDV) is no longer limited to people. It now extends to autonomous systems acting on their behalf — AI agents that can open accounts, submit documents, and bypass checks on their own. Frau

Scientist.com Completes Acquisition by GHO Capital Partners to Accelerate Global R&D Orchestration20.11.2025 14:55:00 EET | Press release

Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform, and GHO Capital Partners LLP (“GHO”), the specialist private equity investor in global healthcare, today announced the successful closing of GHO’s acquisition of Scientist.com. The transaction marks the beginning of an accelerated expansion phase, strengthening Scientist.com’s mission to transform pharmaceutical R&D by streamlining the entire outsourced research lifecycle. “This is a pivotal moment for Scientist.com and for the global research community we support,” said Kevin Lustig, CEO and Chris Petersen, CTO, the founders of Scientist.com. “Partnering with GHO, a team that shares our vision and brings deep expertise in scaling healthcare technology companies, enables us to invest aggressively in our AI-powered orchestration platform and expand our global footprint. Together, we are better positioned than ever to meet growing demand for faster, smarter and more compliant research sourcing.” Fo

SimpliStor™ Solid State Data Recorder Delivers High-Speed, Radiation-Tolerant Storage for Next-Generation Space Missions20.11.2025 14:00:00 EET | Press release

Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the SimpliStor™ Solid State Data Recorder (SSDR), a next-generation, radiation-tolerant data recorder that gives satellite operators, system integrators, and spacecraft designers a faster, smarter, and more resilient way to capture and protect mission-critical information in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120514203/en/ Frontgrade's SimpiStor™ 2.5TB Solid-State Data Recorder High-Throughput Performance SimpliStor delivers 2.5 terabytes of storage and 10Gbps throughput in a compact 3U SpaceVPX package, combining exceptional performance with low power consumption. Users can record more data in less time, with latency under 100 microseconds and continuous “store-to-full” recording, ensuring no data loss during peak operations. A 33-minute continuo

Compass Pathways to Participate in Two Investor Conferences in December20.11.2025 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences: 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on December 2, 2025 Piper Sandler 37th Annual Healthcare Conference – New York, NY: Fireside chat at 1:30pm ET on December 3, 2025 A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatment

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye